Who can respond to treatment? identifying patient characteristics related to heterogeneity of treatment effects

Medical Care

Volumn 48, Issue 6 SUPPL., 2010, Pages

  Kaplan, Sherrie H ^a   Billimek, John ^a   Sorkin, Dara H ^a   Ngo Metzger, Quyen ^a   Greenfield, Sheldon ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Comorbidity; Diabetes; Heterogeneity of treatment effects

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; COHORT ANALYSIS; COMORBIDITY; CONCEPTUAL FRAMEWORK; ETHNICITY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RATING SCALE; RELIABILITY; SELF REPORT; SHORT FORM 36; TREATMENT RESPONSE; AGE; AGED; BLOOD; CHILD; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; CROSS-SECTIONAL STUDY; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; PERSONALITY; PSYCHOLOGICAL ASPECT; SEX DIFFERENCE; SOCIOECONOMICS;

AGE FACTORS; AGED; BLOOD GLUCOSE; CHILD; COMORBIDITY; COMPARATIVE EFFECTIVENESS RESEARCH; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; PERSONALITY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SOCIOECONOMIC FACTORS;

EID: 77953631151     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181d99161     Document Type: Article

References (56)

1. Greenfield S, Billimek J, Pellegrini F, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med. 2009;151:854-860.
2. Greenfield S, Kravitz RL, Duan N, et al. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med. 2007;120:S3-S9.
3. Greenfield S, Kravitz RL. Engaging the implications of subgroup heterogeneity: the increasing inadequacy of randomized trials for guidelines, payment and quality. Washington, DC: Institute of Medicine Report on the Learning Healthcare Environment: National Academy of Sciences; 2007.
4. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82:661-687.
5. Kent D, Hayward R. When Averages hide individual differences in clinical trials: analyzing the results of clinical trials to expose individual patients' risks might help doctors make better treatment decisions. Am Sci. 2007;95:60-68.
6. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratiication. JAMA. 2007;298:1209-1212.
7. Sox HC, Greenield S. Comparative effectiveness research: a report from the institute of medicine. Ann Intern Med. 2009;151:203-205.
8. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl JMed. 2008;358:2545-2559.
9. The Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
10. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360:129-139.
11. Bhatt DL, Fox AA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
12. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669-683. (Pubitemid 43247138)
13. Luce BR, Kramer JM, Goodman SN, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206-210.
14. Peterson ED. Innovation and comparative-effectiveness research in cardiac surgery. N Engl J Med. 2009;361:1897-1899.
15. Hayward RA, Kent DM, Vijan S, et al. Reporting clinical trial results to inform providers, payers, and consumers. Health Affairs. 2005;24:1571-1581.
16. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62:464-475.
17. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624-1632.
18. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. Br Med J. 2008;337:a2390.
19. Karanicolas PJ, Montori VM, Devereaux PJ, et al. A new "mechanistic- practical" framework for designing and interpreting randomized trials. J Clin Epidemiol. 2009;62:479-484.
20. Kent DM, Ruthazer R, Selker HP. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke. 2003;34:464-467.
21. Turner BJ, Hollenbeak CS, Weiner M, et al. Effect of unrelated comorbid conditions on hypertension management. Ann Intern Med. 2008;148: 578-586.
22. Litwin M, Greenfield S, Elkin E, et al. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007;109:1777-1783.
23. Stier DM, Greenfield S, Lubeck DP, et al. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology. 1999;54:424-429.
24. Greenfield S, Sullivan L, Dukes KA, et al. Development and testing of a new measure of case mix for use in office practice. Med Care. 1995;33:AS47-AS55.
25. Hagger MS, Orbell S. A meta-analytic review of the common-sense model Of illness representations. Psychol Health. 2003;18:141-184.
26. Stokols D. Translating social ecological theory into guidelines for community health promotion. Am J Health Promot. 1996;10:282-298.
27. Suls J, Rothman A. Evolution of the biopsychosocial model: prospects and challenges for health psychology. Health Psychol. 2004;23:119-125.
28. Brown AF, Ettner SL, Piette J, et al. Socioeconomic position and health among persons with diabetes mellitus: a conceptual framework and review of the literature. Epidemiol Rev. 2004;26:63-77.
29. Franzini L, Fernandez-Esquer ME. Socioeconomic, cultural, and personal influences on health outcomes in low income Mexican-origin individuals in Texas. Soc Sci Med. 2004;59:1629-1646.
30. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851-858.
31. Kogan SM, Brody GH, Chen Y. Depressive symptomatology mediates the effect of socioeconomic disadvantage on HbA1c among rural African Americans with type 2 diabetes. J Psychosom Res. 2009;67:289-296.
32. Ware JE Jr, Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care. 1995;33:AS264-AS279.
33. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
34. Silliman RA, Bhatti S, Knan A, et al. The care of older persons with diabetes mellitus: families and primary care physicians. J Am Geriatr Soc. 1996;44:1314-1321.
35. Greenfield S, Kaplan SH, Silliman RA, et al. The uses of outcomes research for medical effectiveness, quality of care, and reimbursement in type II diabetes. Diabetes Care. 1994;17(suppl 1):32-39.
36. Brickman AL, Yount SE, Blaney NT, et al. Personality traits and long-term health status: the influence of neuroticism and conscientiousness on renal deterioration in type-1 diabetes. Psychosomatics. 1996;37: 459-468.
37. Hemingway H, Marmot M. Psychosocial factors in the aetiology and prognosis of coronary heart disease: systematic review of prospective cohort studies. Br Med J. 1999;318:1460-1467.
38. Steptoe A, Molloy GJ. Personality and heart disease. Heart. 2007;93: 783-784.
39. Mols F, Denollet J. Type D personality in the general population: a systematic review of health status, mechanisms of disease, and workrelated problems. Health Qual Life Outcomes. 2010;8:9.
40. Yousfi S, Matthews G, Amelang M, et al. Personality and disease: correlations of multiple trait scores with various illnesses. J Health Psychol. 2004;9:627-647.
41. Bagby RM, Quilty LC, Segal ZV, et al. Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. Can J Psychiatry. 2008;53:361-370.
42. Kool S, Schoevers R, de Maat S, et al. Efficacy of pharmacotherapy in depressed patients with and without personality disorders: a systematic review and meta-analysis. J Affect Disord. 2005;88:269-278.
43. Denollet J, Vaes J, Brutsaert DL. Inadequate response to treatment in coronary heart disease: adverse effects of type D personality and younger age on 5-year prognosis and quality of life. Circulation. 2000; 102:630-635.
44. Kaplan SH, Dukes KA, Sullivan LM, et al. Is passivity a risk factor for poor health outcomes? J Gen Intern Med. 1996;11:76.
45. Seeman TE. Personal control and coronary artery disease: how generalized expectancies about control may influence disease risk. J Psychosom Res. 1991;35:661-669.
46. Lachman ME, Weaver SL. The sense of control as a moderator of social class differences in health and well-being. J Pers Soc Psychol. 1998;74: 763-773.
47. Pudrovska T, Schieman S, Pearlin LI, et al. The sense of mastery as a mediator and moderator in the association between economic hardship and health in late life. J Aging Health. 2005;17:643-660.
48. Schieman S, Meersman SC. Neighborhood problems and health among older adults: received and donated social support and the sense of mastery as effect modifiers. J Gerontol B Psychol Sci Soc Sci. 2004;59: S89-S97.
49. Street RL Jr, Krupat E, Bell RA, et al. Beliefs about control in the physician-patient relationship: effect on communication in medical encounters. J Gen Intern Med. 2003;18:609-616.
50. Sherbourne CD, Hays RD, Ordway L, et al. Antecedents of adherence to medical recommendations: results from the Medical Outcomes Study. J Behav Med. 1992;15:447-468.
51. Toobert DJ, Glasgow RE. Assessing diabetes self-management: the summary of diabetes self-care activities questionnaire. In: Bradley C, ed. Handbook of Psychology and Diabetes. Newark, NJ: Harwood Academic Publishers;1994:355-356.
52. SPSS Statistical Software [computer program]. Version 17.0 for Windows. Chicago, IL: SPSS; 2008.
53. Carusoa LB, Sillimana RA, Demissieb S, et al. What can we do to improve physical function in older persons with Type 2 diabetes? J Gerontol A Biol Sci Med Sci. 2000;55:M372-M377.
54. Kaplan SH, Dukes KA, Sullivan LM, et al. Is passivity a risk factor for poor health outcomes? J Gen Intern Med. 1996;11:76.
55. Dimatteo RM, Lepper HD, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000; 160:2101-2107.
56. Ciechanowski PS, Katon WJ, Russo JO. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000;160:3278-3285.